<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04962516</url>
  </required_header>
  <id_info>
    <org_study_id>D2018091</org_study_id>
    <nct_id>NCT04962516</nct_id>
  </id_info>
  <brief_title>Evaluation of the Safety and Efficacy of Single-use Precision Filtered Infusion Sets for Intravenous Infusion</brief_title>
  <official_title>Open, Randomized, Parallel Controlled Clinical Trial to Evaluate the Safety and Efficacy of Single-use Precision Filtered Infusion Sets for Intravenous Infusion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University Third Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Beijing Friendship Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Peking University Third Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a pre-market clinical trial of a single-use precision filter infusion set for&#xD;
      pumps, to evaluate the safety and effectiveness of a single-use precision filter infusion set&#xD;
      for pumps after being used in humans, and to provide clinical evidence for the official&#xD;
      application of the product in China&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This experiment compares the single-use precision filter infusion set produced by Shandong&#xD;
      Xinhua Ande Medical Products Co., Ltd. for the same intended use that has been approved to&#xD;
      market, and compares the performance of the two products in clinical use, the overall pass&#xD;
      rate, and the occurrence of phlebitis Rates and adverse events are used to evaluate the&#xD;
      safety and effectiveness of single-use precision filtration infusion sets for pumps.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Actual">July 1, 2019</completion_date>
  <primary_completion_date type="Actual">December 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>2 hr after injection</time_frame>
    <description>changes in breathing, resting heart rate, blood pressure, body temperature, etc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Vital signs</measure>
    <time_frame>24 hr after injection</time_frame>
    <description>changes in breathing, resting heart rate, blood pressure, body temperature, etc</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events and complications</measure>
    <time_frame>2 hr after injection</time_frame>
    <description>The incidence of adverse events and complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>adverse events and complications</measure>
    <time_frame>24 hr after injection</time_frame>
    <description>The incidence of adverse events and complications</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of heat source reactions</measure>
    <time_frame>2 hr after injection</time_frame>
    <description>Heat source reactions caused by the application of extension tubes, such as nausea, vomiting, chills, fever, etc., are key safety indicators</description>
  </primary_outcome>
  <primary_outcome>
    <measure>number of heat source reactions</measure>
    <time_frame>24 hr after injection</time_frame>
    <description>Heat source reactions caused by the application of extension tubes, such as nausea, vomiting, chills, fever, etc., are key safety indicators</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">168</enrollment>
  <condition>Single-use Precision Filter Infusion Set</condition>
  <arm_group>
    <arm_group_label>Test group</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>single-use precision filtered infusion sets</intervention_name>
    <description>single-use precision filter infusion set (Dalian JMS Medical Apparatus Co., Ltd.)</description>
    <arm_group_label>Test group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>single-use precision filter infusion set with needle</intervention_name>
    <description>single-use precision filter infusion set with needle (Shandong Zhongbao Kang Medical Apparatus Co., Ltd.)</description>
    <arm_group_label>Control group</arm_group_label>
  </intervention>
  <eligibility>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. age 18 years or older, gender not limited;&#xD;
&#xD;
          2. intravenous infusion requiring drug filtration, flow regulation, dosing and extension&#xD;
             of infusion line;&#xD;
&#xD;
          3. not participating in other clinical trials within one month;&#xD;
&#xD;
          4. able to understand the purpose of the trial, voluntarily participate and sign the&#xD;
             informed consent;&#xD;
&#xD;
          5. willing to follow up and evaluate according to the requirements of the trial protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with positive pregnancy test in women of childbearing age or lactating women;&#xD;
&#xD;
          2. Patients with uncontrollable cardiomyopathy, heart failure and unable to tolerate&#xD;
             infusion;&#xD;
&#xD;
          3. Patients with uncontrollable decompensated renal function, especially in the anuric&#xD;
             phase of acute renal failure and unable to tolerate infusion;&#xD;
&#xD;
          4. Patients with uncontrollable extensive inflammation of the lung parenchyma, pulmonary&#xD;
             congestion, pulmonary edema and unable to tolerate infusion;&#xD;
&#xD;
          5. 0.2um size Test devices combined with any of the following drugs or preparations:&#xD;
             fatty milk type, blood products type (blood cells, globulin, etc.), drugs that will&#xD;
             produce insoluble precipitates with each other, etc.; 6, patients who are clinically&#xD;
             infused with very small amounts of drugs (due to residual test line may reduce the&#xD;
             amount of drugs delivered to patients); 7, puncture sites with inflammation, tumors,&#xD;
             trauma, scars, etc.; 8, those who may be allergic to product materials; 9 Patients&#xD;
             with AIDS;&#xD;
&#xD;
        10. Patients with mental disorders; 11. Other patients who are considered by the&#xD;
        investigator to be unsuitable for participation in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baohua Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University Third Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Beijing Friendship Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 27, 2021</study_first_submitted>
  <study_first_submitted_qc>July 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>July 4, 2021</last_update_submitted>
  <last_update_submitted_qc>July 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

